Cancer Institute A national cancer institute
designated cancer center

Major Areas of Research


Hodgkin's Lymphoma

Cancer Epidemiology Program and Cancer Prevention and Control Program researchers have undertaken a number of population-based studies to identify the causes of Hodgkin's Lymphoma (HL) and its many subtypes, as well as factors influencing patient outcome. A number of correlations have been investigated, including:

Non-Hodgkin's Lymphoma

Dr. Ellen Chang is conducting ongoing research in collaboration with colleagues at the Karolinska Institute (including Dr. Hans-Olov Adami) and the Statens Serum Institute (including Dr. Mads Melbye) on a large population-based case-control study of non-Hodgkin lymphoma (NHL). Her previous research includes studies of the roles of diet and alcohol (Cancer Epidemiol Biomarkers Prev 2005;14:512 2005; Cancer Causes Control 15:1067, 2004; Lancet Oncol 6:469, 2005), body mass index (J Natl Cancer Inst 97:210, 2005), medication use (Am J Epidemiol 162:965, 2005), and family history of hematopoietic cancer (J Natl Cancer Inst 97:1466, 2005) in the development of NHL and its histopathologic subtypes; current and future studies will focus on the associations of nutrient intake and Helicobacter Pylori infection with NHL risk.

Stanford researchers and clinicians have helped to define the standard of care for lymphomas worldwide. Today the Lymphoma and Hodgkin’s Disease Research Program continues this legacy through interdisciplinary investigations into immune system cancer and its molecular and genetic origins. The Stanford Cutaneous Lymphoma Collaborative Team has 3 major categories of research focus: epidemiology ; clinical outcomes, newer/better diagnostic, staging, and prognosticating tools; and development of novel therapies .

This document was last modified: Monday, 27-Jun-2011 13:29:24 PDT

Stanford Medicine Resources:

Footer Links: